{"id":925233,"date":"2026-01-08T07:03:05","date_gmt":"2026-01-08T12:03:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\/"},"modified":"2026-01-08T07:03:05","modified_gmt":"2026-01-08T12:03:05","slug":"rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\/","title":{"rendered":"Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit"},"content":{"rendered":"

<\/p>\n

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit<\/b><\/p>\n

Appointment supports AstraZeneca\u2019s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030<\/i><\/b><\/p>\n

WILMINGTON, Del.–(BUSINESS WIRE<\/a>)–
\nAstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit.<\/p>\n

\nSuarez will lead the execution of the Company\u2019s previously announced $50 billion US research, development and manufacturing investment, including construction of a $4.5 billion manufacturing facility in Virginia, AstraZeneca\u2019s largest single manufacturing investment globally.<\/p>\n

\nThe investment underpins AstraZeneca\u2019s goal of generating $80 billion in Total Revenue by 2030, with half expected to come from the US, the Company\u2019s largest market.<\/p>\n

\nSuarez said: \u201cWe are operating at a moment of unprecedented scientific opportunity. Our responsibility is to translate that science into results for patients and for the US healthcare system. By strengthening our US manufacturing and R&D footprint, we will expand access to innovative medicines, create highly skilled jobs, and deliver long-term value.\u201d<\/p>\n

\nSuarez will have full responsibility for AstraZeneca\u2019s US BioPharmaceuticals organization, with accountability for performance, growth and execution across the portfolio.<\/p>\n

\nSuarez brings more than 20 years of experience in the US healthcare sector, with leadership roles spanning commercial, medical and market access functions at AstraZeneca. He returns to the US after serving as Country President for Spain since 2020, where he led one of AstraZeneca\u2019s strongest performing European markets. He expanded Spain\u2019s role in global clinical development and positioned Barcelona as a strategic hub for innovation.<\/p>\n

\nDuring his tenure in Spain, Suarez established a new global hub in Barcelona and launched the AstraZeneca Healthcare Innovation Hub, committing more than \u20ac10 million to digital health and data-driven initiatives focused on translational innovation.<\/p>\n

\nSuarez will be based at AstraZeneca\u2019s US headquarters in Wilmington, Delaware. His appointment is effective immediately.<\/p>\n

Biographical information<\/b><\/p>\n

\nRick Suarez was born in the United States and grew up in New Haven, Connecticut. He joined AstraZeneca in 1999 as a pharmaceutical sales specialist and has worked across many functions of the business including marketing, medical affairs and market access.<\/p>\n

Notes<\/span><\/b><\/p>\n

AstraZeneca<\/b><\/p>\n

\nAstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca\u2019s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca-us.com<\/a> and follow the Company on social media @AstraZeneca<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260108091819\/en\/<\/a><\/span><\/p>\n

Media Inquiries
\n<\/b>
Fiona Cookson +1 212 814 3923<\/p>\n

US Media Mailbox: usmediateam@astrazeneca.com<\/a><\/p>\n

KEYWORDS:<\/b> Delaware Virginia Europe Spain United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Manufacturing Research Other Manufacturing Science Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit Appointment supports AstraZeneca\u2019s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030 WILMINGTON, Del.–(BUSINESS WIRE)– AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit. Suarez will lead the execution of the Company\u2019s previously announced $50 billion US research, development and manufacturing investment, including construction of a $4.5 billion manufacturing facility in Virginia, AstraZeneca\u2019s largest single manufacturing investment globally. The investment underpins AstraZeneca\u2019s goal of generating $80 billion in Total Revenue by 2030, with half expected to come from the US, the Company\u2019s largest market. Suarez said: \u201cWe are operating at a … <\/p>\n

Continue reading “Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-925233","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit Appointment supports AstraZeneca\u2019s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030 WILMINGTON, Del.–(BUSINESS WIRE)– AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit. Suarez will lead the execution of the Company\u2019s previously announced $50 billion US research, development and manufacturing investment, including construction of a $4.5 billion manufacturing facility in Virginia, AstraZeneca\u2019s largest single manufacturing investment globally. The investment underpins AstraZeneca\u2019s goal of generating $80 billion in Total Revenue by 2030, with half expected to come from the US, the Company\u2019s largest market. Suarez said: \u201cWe are operating at a … Continue reading "Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-08T12:03:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260108091819r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit\",\"datePublished\":\"2026-01-08T12:03:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\\\/\"},\"wordCount\":473,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260108091819r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\\\/\",\"name\":\"Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260108091819r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-01-08T12:03:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260108091819r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260108091819r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\/","og_locale":"en_US","og_type":"article","og_title":"Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit - Market Newsdesk","og_description":"Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit Appointment supports AstraZeneca\u2019s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030 WILMINGTON, Del.–(BUSINESS WIRE)– AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit. Suarez will lead the execution of the Company\u2019s previously announced $50 billion US research, development and manufacturing investment, including construction of a $4.5 billion manufacturing facility in Virginia, AstraZeneca\u2019s largest single manufacturing investment globally. The investment underpins AstraZeneca\u2019s goal of generating $80 billion in Total Revenue by 2030, with half expected to come from the US, the Company\u2019s largest market. Suarez said: \u201cWe are operating at a … Continue reading \"Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-08T12:03:05+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260108091819r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit","datePublished":"2026-01-08T12:03:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\/"},"wordCount":473,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260108091819r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\/","name":"Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260108091819r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-01-08T12:03:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260108091819r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260108091819r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rick-r-suarez-appointed-us-president-and-head-of-us-biopharmaceuticals-business-unit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/925233","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=925233"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/925233\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=925233"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=925233"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=925233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}